Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
 & Lead Plaintiff Deadline - April 7, 2017 - EconoTimes)
NEW YORK, Feb. 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (NASDAQ:PETX) and certain of its officers, on behalf of a class who purchased Aratana securities between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/petx.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have adequate manufacturing contracts in place to upkeep manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/petx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
